AI Article Synopsis

  • Corneal neovascularization (CNV) is a major cause of vision loss globally, and existing treatments have limitations and side effects.
  • A new formulation called TAT-MSCm@NanoSU6668 (T-MNS) was developed using nanoparticles of an inhibitor called SU6668, encoded with stem cell membrane vesicles and a cell-penetrating peptide for enhanced targeting.
  • T-MNS showed effective results in treating CNV through eye drops, successfully reducing blood vessel growth and restoring corneal clarity without damaging surrounding eye tissues.

Article Abstract

Corneal neovascularization (CNV) is one of the common blinding factors worldwide, leading to reduced vision or even blindness. However, current treatments such as surgical intervention and anti-VEGF agent therapy still have some shortcomings or evoke some adverse effects. Recently, SU6668, an inhibitor targeting angiogenic tyrosine kinases, has demonstrated growth inhibition of neovascularization. But the hydrophobicity and low ocular bioavailability limit its application in cornea. Hereby, we proposed the preparation of SU6668 pure nanoparticles (NanoSU6668; size ~135 nm) using a super-stable pure-nanomedicine formulation technology (SPFT), which possessed uniform particle size and excellent aqueous dispersion at 1 mg/mL. Furthermore, mesenchymal stem cell membrane vesicle (MSCm) was coated on the surface of NanoSU6668, and then conjugated with TAT cell penetrating peptide, preparing multifunctional TAT-MSCm@NanoSU6668 (T-MNS). The T-MNS at a concentration of 200 µg/mL was treated for CNV via eye drops, and accumulated in blood vessels with a high targeting performance, resulting in elimination of blood vessels and recovery of cornea transparency after 4 days of treatment. Meanwhile, drug safety test confirmed that T-MNS did not cause any damage to cornea, retina and other eye tissues. In conclusion, the T-MNS eye drop had the potential to treat CNV effectively and safely in a low dosing frequency, which broke new ground for CNV theranostics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11129376PMC
http://dx.doi.org/10.1186/s12951-024-02510-8DOI Listing

Publication Analysis

Top Keywords

su6668 pure
8
corneal neovascularization
8
blood vessels
8
pure nanoparticle-based
4
nanoparticle-based eyedrops
4
eyedrops high
4
high drug
4
drug accumulation
4
accumulation long-time
4
long-time treatment
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!